[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercortisolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercortisolism":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,77,107,129,156,180,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100535017","phase-2-evaluating-the-functional-status-of-the-adrenal-glands-with-68gaga-pentixafor-in-hyperaldosteronism-and-hypercortisolism-100535017",false,"NCT06246357","Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism","Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism","* INCLUSION CRITERIA:\n* Must have any of the following:\n\n  * one or more adrenal masses on CT and\u002For MRI and biochemical evidence of excess aldosterone\n\nOR\n\n--ACTH-independent hypercortisolism, with or without adrenal masses on CT and\u002For MRI\n\nOR\n\n* history of ACTH-dependent hypercortisolism (with or without adrenal enlargement)\n* Co-enrollment in 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial.\n* Age \\>=18 years.\n* ECOG performance status \\\u003C= 2.\n* Women of child-bearing potential (WOCBP) and men must agree to use an effective contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) for two weeks prior to \\[68Ga\\]Ga-PentixaFor scan and for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n\n  * Breastfeeding should be discontinued for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n  * Men must agree not to donate sperm for one week after the \\[68Ga\\]Ga-PentixaFor scan.\n* Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening.\n* Uncontrolled intercurrent illness or social situations based on the review of medical history that would limit compliance with study requirements.\n* Contraindications to having an MRI and CT.","ALL","18 Years","120 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nThe adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional.\n\nObjective:\n\nTo see if a new radioactive tracer (\\[68Ga\\]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans.\n\nEligibility:\n\nPeople aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242).\n\nDesign:\n\nParticipants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed.\n\nParticipants will have one PET scan with the study tracer.\n\nThe tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes.\n\nParticipants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan.\n\nParticipants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.",[27,28,29],"Hyperaldosteronism","Hypercortisolism","Cushing s Syndrome",[31,32],"Adenomas","PET Imaging","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2024-09-23",{"date":41,"type":21},"2028-04-01",{"name":43,"class":44},"National Cancer Institute (NCI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100467540","endoscopic-ultrasound-guided-radiofrequency-ablation-in-primary-aldosteronism-100467540","NCT05368090","Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism","Endoscopic Ultrasound-guided Radiofrequency Ablation as a Novel Treatment Option Compared With Adrenalectomy in Left-sided Primary Aldosteronism","Inclusion Criteria all groups\n\n* Signed written informed consent\n* If CT scan shows an adrenal nodule to the same adrenal as AVS lateralisation result: nodule size \\\u003C 4 cm and enhancement criteria for adrenal adenoma (native hounsfield units \\\u003C 10 or relative wash-out \\> 40% or absolute wash-out \\> 60%)\n\nPA unilateral group inclusion criteria:\n\n* Age 18 to 60 years\n* PA diagnosis confirmed according to Endocrine Society PA Guideline criteria\n* AVS lateralisation to left adrenal (lateralisation index ≥ 4,0)\n\nPA \"debulking\" group inclusion criteria:\n\n* Age 18 to 70 years\n* PA diagnosis confirmed according to Endocrine Society PA Guideline criteria\n\nMACS unilateral and debulking group inclusion criteria:\n\n* Age 18 to 80 years\n* MACS diagnosis confirmed according to ENSAT\u002FECE Guideline criteria\n* AVS lateralisation to the left adrenal, and visible left adrenal tumor on CT scan OR bilateral overproduction of cortisol on AVS, and bilateral tumors\u002Fhyperplasia on CT scan (debulking)\n\nExclusion Criteria all groups:\n\n* CT scan suspicion of adrenal malignancy\n* Patient refusal to undergo either EUS-RFA or adrenalectomy","80 Years",{"count":55,"type":21},60,[57],"NA","In this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous cortisol secretion (MACS). Four different study groups will all receive EUS-RFA of left-sided adrenal tumours. Clinical and biochemical outcome as well as procedural safety will be evaluated. In study patients with verified lateralised aldosterone or cortisol overproduction to the left adrenal, outcome will be compared with control groups performing conventional unilateral adrenalectomy.\n\nStudy group 1: PA patients with AVS-verified left sided lateralisation and a EUS-detectable tumour in the left adrenal for EUS-RFA treatment.\n\nStudy group 2: PA patient with suspected left-sided overweight of aldosterone production and a EUS-detectable tumour but without strict lateralisation of their aldosterone overproduction, for EUS-RFA treatment as an aldosterone \"debulking\" procedure.\n\nStudy group 3: patients with MACS with AVS-verified lateralisation of cortisol overproduction to the left adrenal and EUS-detectable tumour for EUS-RFA treatment Study group 4: patients with MACS with bilateral adrenal tumours and verified bilateral overproduction of cortisol for EUS-RFA treatment as a cortisol \"debulking\" procedure.",[60,61,28],"Primary Aldosteronism","Aldosterone-Producing Adenoma",[63,64,65,66],"radio frequency ablation","postoperative hypoaldosteronism","postoperative hypocortisolism","metabolic comorbidity","2026-05-07",{"date":69,"type":37},"2026-05-08",{"date":71,"type":37},"2022-06-03",{"date":73,"type":21},"2028-12-31",{"name":75,"class":76},"Haukeland University Hospital","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":17,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100624680","rems25-study-on-the-use-of-rems-technology-in-diseases-commonly-associated-with-reduced-bone-mineral-density-bmd-100624680","NCT07412782","REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)","Observational Study for the Assessment of Bone Mineral Density (BMD) Using REMS Technology","Inclusion Criteria:\n\n* Written informed consent from adult patients or parents\u002Flegal guardians\n* Age between 5 and 18 years\n* Both sexes and all ethnicities\n* Known condition negatively affecting bone health\n\nExclusion Criteria:\n\n\\- Age below 5 years or over 18 years","5 Years",{"count":86,"type":21},100,[57],"This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free ultrasound technology. Bone health is crucial during childhood, when peak bone mass develops, and reduced BMD is associated with increased fracture risk. DXA is the current reference method but has limitations in children, including radiation exposure and growth-related measurement issues. REMS has been validated in adults and shows promise in pediatrics, despite the lack of reference values. The study is a single-center, national, non-profit interventional study lasting about 12 months. Participants will undergo REMS BMD measurement, clinical history collection, and assessment of anthropometric and pubertal parameters, with prior DXA data collected when available. The primary aim is to describe BMD values measured by REMS in pediatric osteoporosis, with secondary aims including subgroup analyses and comparison with DXA. A sample of 100 patients is planned. Statistical analyses will assess BMD distributions, correlations with clinical variables, and agreement between REMS and DXA using correlation coefficients and Bland-Altman analysis.",[90,91,92,93,94,95,28,96,97],"Osteogenesis Imperfecta","Osteoporosis","Hypogonadisms","Neoplasia","Obesity & Overweight","Malnutrition (Calorie)","Growth Hormone Deficiency (GHD)","Osteopenia","2026-02-13",{"date":100,"type":37},"2026-02-17",{"date":102,"type":37},"2025-12-04",{"date":104,"type":21},"2026-12-31",{"name":106,"class":76},"Meyer Children's Hospital IRCCS",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":45},"100604965","salivary-cortisol-and-hypercortisolism-in-type-2-diabetes-100604965","NCT07156370","Salivary Cortisol and Hypercortisolism in Type 2 Diabetes","Study to Explore the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Assess the Correlation Between Salivary Cortisol and Glucose Levels","Inclusion Criteria:\n\n1. Aged between 18 and 80 years.\n2. Meets the definition of difficult to control type 2 diabetes:\n\nHbA1c level between 7.5% and 11.5%, AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND\u002FOR b.) concomitant hypertension requiring 2 or more anti-hypertension medications.\n\nExclusion Criteria:\n\n1. Patients with Type 1 diabetes, new-onset diabetes (\\\u003C1 year duration), or other specific types of diabetes.\n2. History of systemic glucocorticoid use within the last 3 months (inhaled or topical agents are not exclusionary).\n3. Pregnant or lactating.\n4. Presence of severe cardiac, hepatic, renal, or other major organ dysfunction.\n5. History of acute diabetic complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, within the last 3 months.\n6. Presence of diseases that significantly affect metabolism, such as malignancy or autoimmune disorders.\n7. Inability to tolerate adhesive tape, severe skin conditions at the sensor placement site, or presence of a psychiatric illness or cognitive impairment that would interfere with study compliance.\n8. A known diagnosis of Cushing's syndrome, or currently receiving treatment with any of the following: mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, long-acting octreotide, or pasireotide.\n9. Excessive alcohol consumption (defined as \\>14 units per week for males or \\>7 units per week for females).\n10. Severe, untreated sleep apnea.\n11. Night shift workers (defined as being awake between 11:00 PM and 7:00 AM).\n12. Known allergy or severe reaction to dexamethasone.",{"count":115,"type":21},500,"OBSERVATIONAL","The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies. Additionally, the study will evaluate the correlation between salivary cortisol levels and glycemic control.",[28,119],"Type 2 Diabetes (T2DM)","2025-09-04",{"date":122,"type":37},"2025-09-05",{"date":124,"type":21},"2025-09-01",{"date":126,"type":21},"2027-12-31",{"name":128,"class":76},"Shanghai 6th People's Hospital",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100549170","a-block-and-replace-therapy-with-osilodrostat-and-concomitant-glucocorticoid-replacement-100549170","NCT06430528","A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement","Inclusion Criteria:\n\n* Endogenous Cushing syndrome, either following surgery or not candidates for surgery\n* Under consideration to receive osilodrostat as part of their clinical care\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Treatment with other investigational drugs within 30 days or five half-lives (whichever is longer).\n* A history of hypersensitivity to osilodrostat or therapies of a similar chemical class.","75 Years",{"count":137,"type":21},12,"The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach).\n\nThe investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.",[140,141,28],"Endogenous Cushing Syndrome","Adrenal Insufficiency",[143,144,145,146],"Osilodrostat","Glucocorticoid","Methylprednisolone","Medrol","2025-08-14",{"date":149,"type":37},"2025-08-20",{"date":151,"type":37},"2024-07-19",{"date":153,"type":21},"2027-08",{"name":155,"class":76},"University of Michigan",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":165,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":45},"100372296","impact-of-adrenal-incidentalomas-and-possible-autonomous-cortisol-secretion-on-cardiovascular-and-metabolic-alterations-100372296","NCT04127552","Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations","Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations (ITACA Study)","ITACA","Inclusion Criteria:\n\n* Incidentally detected adrenal mass\n\nExclusion Criteria:\n\n* Patients with overt Cushing's syndrome, pheochromocytoma, Conn syndrome, adrenocortical carcinoma, late-onset congenital adrenal hyperplasia, adrenal metastasis and adrenal hemorrhage\n* Patients taking medications influencing glucocorticoid production or metabolism\n* Patients with psychiatric diseases or alcohol abuse\n* Pregnancy",true,{"count":166,"type":21},68,"The investigators hypothesize that cardiovascular and metabolic alterations can occur in patients with adrenal adenomas and possible Autonomous Cortisol Secretion (pACS). Investigators hypothesize that adrenalectomy in selected patients, following the 2016 European Congress of Endocrinology (ECE) guidelines, can improve metabolic parameters and cardiovascular risks and features.",[169,28,170],"Adrenal Incidentaloma","Adrenal Tumor","2025-03-24",{"date":173,"type":37},"2025-03-28",{"date":175,"type":37},"2019-01-02",{"date":177,"type":21},"2025-12-31",{"name":179,"class":76},"University of Roma La Sapienza",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100570022","osilodrostat-therapy-and-11c-methionine-pet-to-improve-corticotroph-adenoma-detection-100570022","NCT06701838","Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection","Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease","OPTIMAL","Inclusion Criteria:\n\nAll participants must meet all of the following inclusion criteria:\n\n* age 18 years and older newly diagnosed with Cushing's disease and no\u002F an equivocal surgical target on MRI pituitary or\n* age 18 years and older and previously undergone pituitary surgery for Cushing's disease and clinical and biochemical evidence of persistent\u002F recurrent hypercortisolaemia and no\u002F an equivocal surgical target on MRI pituitary.\n\nExclusion Criteria:\n\nPotential participants will be ineligible to enter the study if they meet any of the following exclusion criteria:\n\n* Absolute contraindication to osilodrostat therapy and\u002For 11C methionine PET.\n* Pregnancy or unwillingness to use secure contraception for the study duration (female participants only).\n* Unable to comply with study visit schedule.",{"count":189,"type":21},15,"Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress. But too much cortisol can lead to problems like weight gain, high blood pressure, diabetes, and changes in appearance, such as a round face or a hump on the back. People with Cushing's disease often gain weight around their belly and may get stretch marks. They might also feel emotional changes, tiredness, or weakness. This disease is usually caused by a small, non-cancerous growth in the pituitary gland called a 'pituitary adenoma.' The pituitary gland is a small organ at the base of the brain and controls many important functions.\n\nWhen someone is diagnosed with Cushing's disease, doctors typically use an MRI scan to look for the adenoma in the pituitary gland. If found, the adenoma can often be removed through surgery, which often cures the disease. This is the standard treatment for patients with Cushing's disease. However, MRIs only find the adenoma in about 60% of the time. If surgery isn't possible because the adenoma can't be located, doctors may use medication to lower cortisol levels.\n\nIn addition to the MRI, doctors might use a special PET\u002FCT scan to find the adenoma. This PET\u002FCT scan is not available everywhere, so the investigators refer our patients to Cambridge Hospital for this scan, which uses a special dye called 11C-methionine.\n\nThe investigators then review the scan with the teams from Imperial and Cambridge. If the PET\u002FCT scan shows where the adenoma is, the patient will be offered surgery. However, finding the adenoma can be challenging because they are often small and hard to distinguish from normal tissue.\n\nIf the adenoma isn't visible, the investigators will use medical treatment to lower cortisol. After a period of medical treatment, another MRI scan and PET\u002FCT scan will be done to see if the adenoma has become clearer. This second PET\u002FCT scan would not normally be part of routine clinical care. The investigators will then compare the results of the two scans to see if the special dye is showing a stronger signal, which can help us find the adenoma more accurately and improve the chance of curing Cushing's disease with surgery.",[192,28,193,194],"Cushing's Disease","Pituitary Adenoma","Pituitary ACTH Secreting Adenoma",[196,143,197,198],"Cushing's disease","11C-methionine PET","Corticotroph adenoma","NOT_YET_RECRUITING","2024-11-28",{"date":202,"type":37},"2024-12-03",{"date":202,"type":21},{"date":205,"type":21},"2026-07-05",{"name":207,"class":76},"Imperial College London",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":45},"100554199","dynamic-hormone-profiling-and-multimodal-data-capture-in-primary-aldosteronism-100554199","NCT06495983","Dynamic Hormone Profiling and Multimodal Data Capture in Primary Aldosteronism","Inclusion criteria Age 18 to 70 years Suspected PA admitted for diagnostic saline infusion testing or confirmed PA diagnosis according to Endocrine Society criteria.. Written informed consent\n\nExclusion criteria\n\n* Age \\\u003C18 or \\> 70 years.\n* Pregnancy.\n* Known adrenal failure and\u002For on steroid therapy (oral, inhaled, parenteral or topical) or other interfering medication.","70 Years",{"count":20,"type":21},"This study is a observational study applying 24-hour microdialysis methodology to perform dynamic multisteroid adrenal hormone profiling of patients with suspected or confirmed PA. Simultaneous registration of blood pressure, tissue glucose, sleep pattern, activity level and food intake registration may be performed. The overall objective is to develop a novel, sensitive, fast and user-friendly diagnostic procedure for PA, using multimodal data capture including dynamic multisteroid hormone profiling from microdialysis fluid.",[218,60,28],"Mineralocorticoid Excess",[220],"aldosterone","2024-07-03",{"date":223,"type":37},"2024-07-11",{"date":225,"type":37},"2024-06-01",{"date":227,"type":21},"2028-12",{"name":75,"class":76}]